Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;104(6):e256-e259.
doi: 10.3324/haematol.2018.207027. Epub 2018 Dec 13.

New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease

Luca Aresu  1 , Serena Ferraresso  2 , Laura Marconato  3 , Luciano Cascione  4   5 , Sara Napoli  4 , Eugenio Gaudio  4 , Ivo Kwee  4   5   6 , Chiara Tarantelli  4 , Andrea Testa  7 , Chiara Maniaci  7   8 , Alessio Ciulli  7 , Petra Hillmann  9 , Thomas Bohnacker  10 , Matthias P Wymann  10 , Stefano Comazzi  11 , Massimo Milan  2 , Fulvio Riondato  12 , Giulia Dalla Rovere  2 , Mery Giantin  2 , Diana Giannuzzi  2 , Francesco Bertoni  13
Affiliations

New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease

Luca Aresu et al. Haematologica. 2019 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of a potential nuclear factor-κB activation pathway obtained by RNA-sequencing analysis in canine diffuse large B-cell lymphomas. Red, upregulated genes. Green, downregulated genes. Yellow, genes that are neither upregulated or downregulated.
Figure 2.
Figure 2.
Unsupervised clustering of canine diffuse large B-cell lymphoma RNA-sequencing data and prognostic impact of PD-L1 and PD-1 expression. (A) Multidimensional scaling plot of all the samples demonstrated a clear separation between normal B cells (green dots) and canine diffuse large B-cell lymphomas (cDLBCL) (red dots). (B) Two cDLBCL subgroups (blue and red) were defined by hierarchical clustering. (C,D) Kaplan-Meier plots of overall survival (C) and event-free survival (D) of cDLBCL grouped on the basis of their RNA-sequencing profiles. (E-H) Prognostic impact of PD-L1 tumor expression and PD-1 residual lymphocyte expression on overall survival and event-free survival in cDLBCL: Kaplan-Meier plots of overall survival (E,G) and event-free survival (F,H) based on immunohistochemical scores of PDL-1 and PD-1, respectively.
See this image and copyright information in PMC

References

    1. Aresu L. Canine Lymphoma, More than a morphological diagnosis: what we have learned about diffuse large B-cell lymphoma. Front Vet Sci. 2016;3:77. - PMC - PubMed
    1. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. - PubMed
    1. Harrington BK, Gardner HL, Izumi R, et al. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-Hodgkin lymphoma. PLoS One. 2016;11(7):e0159607. - PMC - PubMed
    1. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080. - PMC - PubMed
    1. Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131(21):2307–2319. - PMC - PubMed

Publication types

Substances